BioNova

What BioNova does

BioNova Medical, Inc. is a privately held medical device company founded in 2011 and headquartered in Germantown, Tennessee. The company specializes in chitosan-based wound care products, with a portfolio comprising two FDA-regulated devices: Foundation DRS Solo, a biodegradable dermal regeneration scaffold combining chitosan with glycosaminoglycan (chondroitin sulfate) for accelerated healing of full and partial thickness wounds; and Sentrex BioSponge, a hydrophilic wound management device designed for rapid hydration treatment of moderate to heavy exuding wounds. The core technology platform is protected by US Patent #8,993,540 and leverages a proprietary manufacturing process to produce scaffolds with optimized porosity for cellular invasion and neoangiogenesis. Foundation DRS is positioned as a collagen-free alternative to conventional dermal scaffolds, supported by preclinical evidence from porcine full-thickness wound model evaluations.

The company targets healthcare providers and physicians specializing in wound care, including hospital systems, wound care centers, and individual clinical practices treating chronic wounds (diabetic ulcers, pressure ulcers, venous ulcers) and acute wounds (burns, trauma, surgical wounds). BioNova operates a sales-led go-to-market model, distributing product brochures and Instructions for Use (IFU) documents through its website and engaging healthcare professionals directly for product inquiries and orders. Pricing is not publicly disclosed, and the company sells exclusively within the United States with no global footprint claim.

BioNova's business model is traditional medical device hardware sales, with revenue derived from direct sales of Foundation DRS Solo and Sentrex BioSponge to clinical customers. The company has raised approximately $2.9M cumulatively from Innova Memphis across multiple funding rounds between 2011 and 2021, with no subsequent capital raises disclosed. Leadership consists of CEO William Austin. The firm operates with a lean team of 1–10 employees and has no disclosed partnerships, distribution agreements, or institutional investors beyond Innova Memphis. The 2026 copyright notice on the company website indicates active operations.

Name

BioNova

Legal name

Bionova Medical, Inc.

Website

https://bionovamedical.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

BioNova Medical is a privately held medical device company that develops and sells chitosan-based wound care products — Foundation DRS Solo and Sentrex BioSponge — directly to US physicians and healthcare providers treating chronic and acute wounds.

Ownership category

akta.pro rank

Product category

Advanced Wound Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Wound care devices
• Dermal regeneration scaffolds
• Chitosan biomaterials
• Medical device manufacturing
• Advanced wound management

Headquarters

HQ city

Germantown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Medical Device Sales: Bionova Medical generates revenue through the sale of FDA-regulated medical devices for wound care applications, specifically the Foundation DRS dermal regeneration scaffolds and Sentrex BioSponge wound management products. Products are sold directly to healthcare providers and physicians who treat chronic and acute wounds. The revenue model appears to be traditional medical device sales with direct clinical customer engagement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Bionova Medical develops and manufactures FDA-regulated chitosan-based medical devices for advanced wound care. Its product portfolio consists of two primary offerings: Foundation DRS Solo, a biodegradable dermal regeneration scaffold combined with glycosaminoglycan (chondroitin sulfate) for full and partial thickness wounds, and Sentrex BioSponge, a hydrophilic wound management device with rapid hydration capability for moderate to heavy exuding wounds. Products are sold directly to healthcare providers and physicians treating chronic and acute wounds.

Product overview

BioNova Medical is a medical device company offering wound care solutions. Its product portfolio consists of two primary chitosan-based medical devices: Foundation DRS Solo (a dermal regeneration scaffold that promotes accelerated wound healing through optimal porosity for cellular invasion and neoangiogenesis) and Sentrex BioSponge (a hydrophilic wound management device enabling rapid hydration treatment for moderate to heavy exuding wounds). Both products leverage chitosan technology but serve distinct wound care applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Foundation DRS Solo A novel, biodegradable chitosan-based dermal regeneration scaffold (DRS) combined with glycosaminoglycan (chondroitin sulfate), manufactured using a patented process that yields an optimal pore size to promote cellular invasion and neoangiogenesis. Indicated for full and partial thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, burns, donor sites, surgical wounds, and trauma wounds. Can be applied dry or hydrated with saline, and is available in multiple sizes. Sold to physicians and wound care clinicians.
• Sentrex BioSponge A hydrophilic wound management device that combines chitosan with a proprietary manufacturing process to enable rapid hydration in solution for expanded treatment options. Indicated for traumatic injury sites, surgical sites, pressure ulcers, diabetic foot ulcers, full and partial thickness wounds, trauma wounds, burns, and wound bed preparation. Suitable for moderate to heavy exuding wounds and can be cut to size prior to hydration. Sold to physicians and wound care clinicians.

Quantifiable outcome

• Evidence of near complete epithelialization at day 14 in porcine full thickness wound model evaluation

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Organogenesis Holdings: Pure-play advanced wound care and regenerative medicine company offering skin substitutes (Apligraf, Dermagraft, PuraPly). Directly competes with BioNova's Foundation DRS in the cellular and tissue-based wound care segment sold to wound care centers and hospitals.
• Integra LifeSciences: Markets Integra Dermal Regeneration Template, a collagen-GAG (glycosaminoglycan) matrix for skin regeneration—technologically the closest analog to BioNova's chitosan-GAG Foundation DRS, addressing the same dermal regeneration use case.
• MiMedx Group: Sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for chronic wound care, including diabetic foot ulcers and venous leg ulcers—directly overlapping with BioNova's Foundation DRS indications and target customers.

Broad incumbents

• Smith & Nephew: Global advanced wound care leader offering a broad portfolio including Allevyn, PICO negative pressure wound therapy, and collagen-based scaffolds. Sells into the same wound care centers and hospitals as BioNova through a far larger sales organization.
• ConvaTec Group: Major wound therapeutics player with AQUACEL, Foam, and newer biologic/skin substitute products sold through hospital and home care channels. Overlaps with BioNova in chronic wound dressings and tissue-based products.
• Mölnlycke Health Care: Privately held Swedish wound care and surgical solutions leader with Mepilex, Avance, and other advanced wound care brands. Operates globally with established hospital contracts that BioNova would compete against in the US market.
• Coloplast: Danish wound and ostomy care major selling Biatain, Conveen, and other advanced wound dressings to hospitals and home care providers. Direct overlap with BioNova's chronic wound care customer base.
• 3M Health Care (Solventum): Post-spin 3M health care business (Solventum) selling advanced wound dressings and skin protectants into the same hospital procurement channels BioNova targets. A large incumbent that competes for formulary share in standard wound care.

Emerging players

• Vericel Corporation: Commercial-stage cellular therapy company with MACI (cartilage repair) and Epicel (severe burns) — adjacent regenerative medicine technology targeting similar burn and chronic wound indications as BioNova's Foundation DRS.
• AlloSource: Non-profit allograft producer offering skin substitute products for wound care and burn treatment. Competes in the same clinical use cases as BioNova, particularly for burns and diabetic foot ulcers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bionova-medical-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioNova